ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

Srivastava, Shashikant; Deshpande, Devyani; Magombedze, Gesham; Gumbo, Tawanda*
Clinical Infectious Diseases2018-12-15DOI: 10.1093/cid/ciy627
16被引5阅读
引用收藏
分享

摘要

Background. One approach that could increase the efficacy and reduce the duration of antituberculosis therapy is pharmacokinetics/pharmacodynamics-based optimization of doses. However, this could increase toxicity. Methods. We mimicked the concentration-time profiles achieved by human equivalent doses of moxifloxacin 800 mg/day, rifampin 1800 mg/day, and pyrazinamide 4000 mg/day (high-dose regimen) vs isoniazid 300 mg/day, rifampin 600 mg/day, and pyrazinamide 2000 mg/day (standard therapy) in bactericidal and sterilizing effect studies in the hollow fiber system model of tuberculosis (HFS-TB). In an intracellular Mycobacterium tuberculosis (Mtb) HFS-TB experiment, we added a 3-dimensional human organotypic liver to determine potential hepatotoxicity of the high-dose regimen, based on lactate dehydrogenase (LDH). Treatment lasted 28 days and Mtb bacterial burden was based on colony counts. We calculated the time to extinction (TTE) of the Mtb population in the HFS-TB and used morphism-based transformation and Latin hypercube sampling to identify the minimum therapy duration in patients. Results. The kill rate of standard therapy in the bactericidal effect and sterilizing effect experiments were 0.97 (95% confidence interval [CI], .91-.99) log(10) colony-forming units (CFU)/mL/day, and 0.56 (95% CI, .49-.59) log(10) CFU/mL/day, respectively. The high-dose regimen's bactericidal and sterilizing effect kill rates were 0.99 (95% CI, .96-.99) log(10) CFU/mL/day and 0.72 (95% CI, .56-.79) log(10) CFU/mL/day, respectively. The upper confidence bound for TTE in patients was 4.5-5 months for standard therapy vs 3.7 months on the high-dose regimen. There were no differences in LDH concentrations between the 2 regimens at any time point (P > .05). Conclusions. The high-dose regimen may moderately shorten therapy without increased hepatotoxicity compared to standard therapy.

学科与关键词

关键词
3D liverliver toxicitymathematical modelingtime to extinctionhollow fiber system model
相关
加载中…
  • Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges
    Magombedze, Gesham; Pasipanodya, Jotam G.; Srivastava, Shashikant; Deshpande, Devyani; Visser, Marianne E.; Chigutsa, Emmanuel; McIlleron, Helen; Gumbo, Tawanda*Clinical Infectious Diseases, 2018, 67: S349-S358.被引 23
  • Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin
    Goutelle, Sylvain*; Bourguignon, Laurent; Jelliffe, Roger W.; Conte, John E., Jr.; Maire, PascalJournal of Theoretical Biology, 2011, 282(1): 80-92.被引 22
  • High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB
    Nie, Qi; Tao, Lixuan; Li, Yingying; Chen, Nanshan; Chen, Hua; Zhou, Yong; Wang, Yanqiu; Chen, Huidong; Tang, Qiuping; Wang, Xianguang*; Huang, Chaolin*; Yang, Chengfeng*INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 115: 142-148.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Infectious Diseases
发表日期
2018-12-15
卷期
第 67 卷
页码
S359-S364
DOI
10.1093/cid/ciy627
语言
ENGLISH
期刊等级
Q1
成果收录
SCIE
资助标注
National Institutes of Health (NIH) via the NIH Director New Innovator Award (National Institute of General Medical Sciences) [DP2 OD001886]; National Institute of Allergy and Infectious Diseases [R01 AI079497, R56 AI111985]

作者

  • S

    Srivastava, Shashikant (第一作者)

  • D

    Deshpande, Devyani

查看全部 4 位作者收起作者
  • M

    Magombedze, Gesham

  • G

    Gumbo, Tawanda (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417